.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 4,152,448

« Back to Dashboard

Details for Patent: 4,152,448

Title: Method and composition for the treatment of a condition of the gastro intestinal tract
Abstract:There is described a method of treatment of conditions of the gastro intestinal tract, in which conditions allergy or immune reactions play a contributory part, which method comprises per os administration of a compound of the formula I ##STR1## and therapeutically acceptable salts, esters and amides thereof, wherein X is a polymethylene chain containing 3 to 7 carbon atoms inclusive, which chain may be substituted by an --OH group, (as active ingredient), to a patient having such a condition.
Inventor(s): Wardell; George (Loughborough, GB2)
Assignee: Fisons Limited (London, GB2)
Filing Date:Dec 29, 1976
Application Number:05/755,606
Claims:1. A method of treatment of a condition of the gastro-intestinal tract selected from the group consisting of Crohn's disease, atrophic gastritis, ulcerative colites, proctitis, coeliac disease, regional ileitis, peptic ulceration, irritable bowel syndrome and gastro-intestinal bleeding induced by the administration of an anti-inflammatory, which method comprises per os administration of a daily dosage of from 20 to 4,000 mg. of a member selected from the group consisting of a compound of the formula ##STR3## a therapeutically acceptable salt, an alkyl C 1 to 10 ester, a mono-alkyl C 1 to 10 amide, a di-alkyl C 1 to 10 amide and an unsubstituted amide thereof, wherein X is a polymethylene chain containing 3 to 7 carbon atoms inclusive, which chain may be substituted by an --OH group, to a patient having such a condition.

2. A method according to claim 1 wherein the compound is 1,3-bis(2-carboxy-chromon-5-yloxy)-2-hydroxypropane or a pharmaceutically acceptable salt thereof.

3. A method according to claim 1 wherein the compound is 1,3-bis(2-carboxy-chromon-7-yloxy)-2-hydroxypropane or a pharmaceutically acceptable salt thereof.

4. A method according to claim 1 wherein the pharmaceutically acceptable salt is an ammonium, alkali metal or alkaline earth metal salt.

5. A method according to claim 1, wherein the patient receives unit dosages of from 20 to 1000 mg. of the active ingredient.

6. A method according to claim 5 wherein the unit doses are from 100 to 750 mg. of active ingredient.

7. A method according to claim 5, wherein the unit doses are from 200 to 500 mg. of active ingredient.

8. A method according to claim 1 in which the patient receives from 20 to 250 mg. of the active ingredient 2 to 4 times a day.

9. A method according to claim 1 wherein the condition treated is Crohn's disease.

10. A method according to claim 1 wherein the condition treated is atrophic gastritis.

11. A method according to claim 1 wherein the condition treated is ulcerative colitis.

12. A method according to claim 1 wherein the condition treated is proctitis.

13. A method according to claim 1 wherein the condition treated is coeliac disease.

14. A method according to claim 1 wherein the condition treated is regional ileitis.

15. A method according to claim 1 wherein the condition treated is peptic ulceration.

16. A method according to claim 1 wherein the condition treated is irritable bowel syndrome.

17. A method according to claim 1 wherein the condition treated is gastrointestinal bleeding induced by the administration of an anti-inflammatory.

18. A method for the treatment of a condition of the gastro-intestinal tract selected from the group consisting of Crohn's disease, ulcerative colitis, proctitis, irritable bowel syndrome and gastro-intestinal bleeding induced by the administration of an anti-inflammatory, which method comprises administering to the gastro-intestinal tract of a patient suffering from said condition a daily dosage of from 20 to 4,000 mg. of a member selected from the group consisting of a compound of the formula ##STR4## a therapeutically acceptable salt, an alkyl C 1 to 10 ester, a mono-alkyl C 1 to 10 amide, a di-alkyl C 1 to 10 amide and an unsubstituted amide thereof, wherein X is a polymethylene chain containing 3 to 7 carbon atoms inclusive, which chain may be substituted by an --OH group.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc